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In Brief
Sancho et al. show that pancreatic cancer
stem cells (CSCs) are especially
vulnerable to mitochondrial-targeted
therapies (i.e., metformin) due to their
strong reliance on oxidative metabolism.
The MYC/PGC-1a balance acts as the
main determinant for this OXPHOS
dependency, and genetic/
pharmacological targeting of MYC
restores metformin response in resistant
CSCs.
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The anti-diabetic drug metformin targets pancreatic
cancer stem cells (CSCs), but not their differentiated
progenies (non-CSCs), which may be related to
distinct metabolic phenotypes. Here we conclusively
demonstrate that while non-CSCs were highly glyco-
lytic, CSCs were dependent on oxidative metabolism
(OXPHOS)withvery limitedmetabolicplasticity. Thus,
mitochondrial inhibition, e.g., by metformin, trans-
lated intoenergycrisisandapoptosis.However, resis-
tant CSCclones eventually emergedduring treatment
with metformin due to their intermediate glycolytic/
respiratory phenotype. Mechanistically, suppression
of MYC and subsequent increase of PGC-1a were
identified as key determinants for the OXPHOS de-
pendency of CSCs, which was abolished in resistant
CSC clones. Intriguingly, no resistance was observed
for the mitochondrial ROS inducer menadione and
resistance could also be prevented/reversed for met-
formin by genetic/pharmacological inhibition of MYC.
Thus, the specific metabolic features of pancreatic
CSCs are amendable to therapeutic intervention and
could provide the basis for developing more effective
therapies to combat this lethal cancer.
INTRODUCTION
Patients with pancreatic ductal adenocarcinoma (PDAC) suffer
from very poor outcome, and the incidence is still rising, presum-
ably related to the increased prevalence of diabetes and meta-
bolic syndrome as major risk factors, which could make it the
second most frequent cause of cancer death by 2030 (Rahib
et al., 2014). The vast majority of patients is diagnosed at
advanced stage and dies within 12 months due to lack of effec-
tive treatments (Siegel et al., 2012). During this time, many pa-
tients also suffer from rapidly declining performance as well as590 Cell Metabolism 22, 590–605, October 6, 2015 ª2015 Elsevier Incachexia so that palliative care becomes the prevailing approach
for these patients (Hidalgo, 2010). Consequently, PDAC repre-
sents a major unmet medical need with strong socioeconomic
and humanitarian implications.
At least one possible explanation for thepooroutcomeofPDAC
is that only scant attention has been paid to targeting cancer stem
cells (CSCs) asasmall, but highly tumorigenicandmetastatic sub-
population of cancer cells. Indeed, convincing evidence now
demonstrates that cancer heterogeneity not only is generated
by genetically distinct subclones, but is also driven by phenotypic
and functional heterogeneity within each subclone, resulting in a
hierarchical organization of the tumor (Hermann et al., 2007; Li
et al., 2007; Lonardo et al., 2011). At the apex of this hierarchy
are populations of CSCs capable of self-renewal, bearing long-
term in vivo tumorigenicity as well as generating more differenti-
ated progenies constituting epigenetically defined intraclonal
bulk (Miranda-Lorenzo et al., 2014). Evenmore importantly, these
cells determine themetastaticbehavior ofPDACand represent an
important source for disease relapse (Hermannet al., 2007). Thus,
targetingCSCsshould represent an integral component for devel-
oping more effective treatment strategies (Gallmeier et al., 2011;
Lonardo et al., 2011; Mueller et al., 2009).
We have recently demonstrated that these heterogeneous
populations of pancreatic cancer cells differ in their response
to metformin (Lonardo et al., 2013). While for the bulk of more
differentiated cancer cells (non-CSCs) metformin induced cell-
cycle arrest, CSCs actually underwent rapid apoptotic death.
Subsequent in vivo studies in established patient-derived xeno-
grafts (PDX) showed that metformin stalled tumor progression or
even induced disease regression. These data suggested a
distinct metabolic phenotype for CSCs and, indeed, here we
demonstrate that pancreatic CSCs strongly depend on the mito-
chondrial oxidative phosphorylation (OXPHOS), whereas non-
CSCs mostly rely on glycolysis. Interestingly, CSCs showed
reduced metabolic plasticity based on their limited ability to
switch to glycolysis upon mitochondrial inhibition. This was
related to reduced levels of c-MYC expression and inversely
increased levels of PGC-1a in CSCs versus non-CSCs. How-
ever, eventually tumors relapsed under metformin due to
emergence of resistant CSCs with an intermediate metabolicc.
Figure 1. Pancreatic CSCs Display Distinct Metabolic Features
(A) Heatmap of 60metabolism-related genes identified by RNA-seq using five primary PDAC cultures (PDX-185, 215, 253, 265, and 354) grown as either adherent
(Adh) or anchorage-independent cultures (spheres, Sph) analyzed in biological duplicates.
(B) Representative samples from the RNA-seq experiment (PDX-215, 253, 354) as well as CD133/+ sorted cells from the same PDXs were validated by
real-time PCR.
(C) Mitochondrial mass as determined by flow cytometry using MitoTracker Deep Red-FM. Representative plots.
(legend continued on next page)
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phenotype with increased c-MYC expression. Intriguingly, ge-
netic or pharmacological targeting of c-MYC inhibited/reversed
this phenotype, suggesting a multimodal strategy for most effi-
cient metabolic targeting of pancreatic CSCs.
RESULTS
Pancreatic CSCs Display Metabolic Features
Compatible with Oxidative Metabolism
To define the metabolic features of cells enriched for CSC, we
used anchorage-independent sphere cultures (spheres) versus
mostly differentiated cells in adherent cultures (adherent cells)
Figure S1A); we first performed RNA-seq analyses for primary
cultures derived from five different PDX models (Jimeno et al.,
2009; Lonardo et al., 2011). A heatmap selecting a total of 60
metabolism-related genes differentially expressed in spheres
versus adherent cells suggested distinct metabolic phenotypes
(Figures 1A and S1B). Besides upregulation of genes related to
glycosylation and lipid metabolism, spheres also displayed
enhanced expression for several TCA enzymes and mitochon-
drial OXPHOS components. In contrast, adherent cells showed
upregulation of genes related to glycolysis, pentose phosphate
pathway (PPP), and amino acid synthesis. Data were confirmed
by qRT-PCR or PCR array designed for carbohydrate meta-
bolism using spheres and CD133+ cells in order to further enrich
for CSC, respectively (Figure 1B).
Consistently, spheres or CD133+ cells showed increased
mitochondrial mass, but reduced glucose uptake, lactate pro-
duction (both in normoxic or hypoxic conditions), and mitochon-
drial ROS levels (Figures 1C–1E, S1C, and S1D). In addition, their
NADP/NADPH ratio was increased compared to adherent
or CD133– cells (Figure 1F), in line with the observed lower
expression of PPP enzymes. Spheres were also less sensitive
to metabolic challenges such as glucose or glutamine depriva-
tion or inhibition of glycolysis (Figures 1G and S1E).
Next, we performed 13C-glucose (U-13C-Glc) flux analyses us-
ing nuclear magnetic resonance (NMR) spectroscopy for super-
natants or gas chromatography-mass spectrometry (GC-MS)
for cell extracts. Notably, for all experiments, both spheres and
adherent cells were preincubated in serum-free conditions, re-
sulting in similar proliferation levels (Figure S2A) and cellular
viability (data not shown). Glucose flux analysis demonstrated
reduced glucose uptake and 13C-lactate release in spheres (Fig-
ure S2B) indicative of diminished glycolytic flux. These changes
detected in the supernatant were corroborated by measure-
ments in respective cellular extracts, showing in spheres a lower
flux of 13C-Glc towards lactate (Figure S2C). Interestingly, 13C la-
beling of Ribose-5-P was also reduced in spheres, confirming a
diminished activity of the PPP in CSC-enriched conditions (Fig-
ure S2D). In contrast, the glucose-derived 13C label was signifi-
cantly enriched in theKrebscycle intermediates succinate, fuma-
rate, malate, and citrate (Figures S2E–S2H). Thus, CSC-enriched(D) Glucose uptake by 2-NBDG incorporation by flow cytometry. Representative
(E) Lactate production.
(F) NADP/NADPH ratio.
(G) Number of apoptotic cells after 72 hr of incubation in the indicated condition
In (C), (D), and (G), CSCs represent CSC-enriched sphere cultures (Sph) or CD133
Data in (B), (E), (F), and (G) are presented as mean ± SEM. See also Figure S1.
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ofglucose through theKrebscycle,while adherent cells consume
more glucose and subsequently showhigher flux towards lactate
and PPP, consistent with a ‘‘Warburg effect-like’’ profile.
CSCs Bear Enhanced Mitochondrial Respiration and
Impaired Metabolic Plasticity
To functionally validate these findings that suggest an enhanced
mitochondrial activity of CSCs versus non-CSCs, we measured
their oxygen consumption rates (OCR) in the presence or
absence of distinct inhibitors of mitochondrial function (Figures
2A and S3A). Baseline OCR was significantly increased in
sphere-derived or CD133+ cells isolated from five different
tumors as compared to their differentiated counterparts (Fig-
ure S3B). Specifically, while the non-mitochondrial oxygen
consumption was also significantly higher in CSC-enriching con-
ditions, the differences for mitochondrial oxygen consumption
were even more striking (Figures 2B, S3B, and S3C). To ensure
strict validity of this key finding, we took several measures. First,
we excluded any impact of culture conditions by reproducing the
data in cells derived from the same primary culture and sorted for
the CSC markers CD133 or autofluorescence, respectively (Fig-
ures 2B and S3B–S3D). Second, we validated the data in cells
derived from freshly digested tumors (CD133– versus CD133+),
also excluding potential cell culture artifact. Third, we ruled out
a potential influence of intratumoral heterogeneity by reproduc-
ing above data derived from the heterogeneous parental PDX-
185 in a tumor that arose from a single CSC originally isolated
from PDX-185. Even though basal OCR slightly differed between
the polyclonal parental tumor and the monoclonal derivative tu-
mor, suggestive of an interdependence of the respective genetic
background and the respiratory phenotype, differences in base-
line OCR between CSCs and non-CSCs remained significant,
confirming the robustness of our findings.
Cancer cells regularly increase their glycolytic activity to main-
tain stable ATP levels when mitochondrial function is inhibited
(Wu et al., 2007), which could also be reproduced for pancreatic
non-CSCs and translated into increased lactate production as
evidenced by a concomitant ECAR rise (Figure 2C). A similar
response was observed upon Glc injection for starved non-
CSCs (Figure 2D). In contrast, such increase in ECAR was
severely blunted in CSCs (Figures 2C–2E and S3D, right panel).
Importantly, findings were independent of culture conditions,
origin of the cells (in vitro versus in vivo), and genetic back-
ground, even though differences were less prominent for the
monoclonal single-cell-derived tumor (Figure 2E). This limited
glycolytic capacity of CSCs eventually translated into a signifi-
cant drop in ATP levels and subsequent energy crisis upon
mitochondrial inhibition in spheres, whereas adherent cells
showed only a minor response (Figure 2F). On the other hand,
inhibition of glycolysis caused a marked drop in ATP levels
in adherent cells, demonstrating strong dependence on theplots.
s. Glc, glucose; Gln, glutamine.
+ cells, while differentiated cultures are adherent cultures (Adh) or CD133– cells.
c.
Figure 2. CSCs Bear Enhanced Mitochondrial Respiration and Impaired Glycolytic Plasticity
Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were determined using the XF Extracellular Flux Analyzer comparing differentiated
cells (Adh or CD133–) and CSC-enriched cultures (Sph or CD133+). When indicated, CD133– and CD133+ cells were sorted from primary sphere cultures (CD133,
cell culture) or freshly digested tumors (CD133, tumor) from either the parental 185 PDX (185) or a tumor obtained upon injection of a single CSC from a 185
primary culture (185sc).
(A) Oxygen consumption rate (OCR). Pooled data for sorted cells from PDX-215, 253, and 354 primary cultures, which were subsequently treated by injection of
oligomycin (O), FCCP (F), and antimycin plus rotenone (A+R) into the culture medium.
(B) Mitochondrial oxygen consumption (ATP-linked + proton leak).
(legend continued on next page)
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Warburg effect, while the effect on spheres was minor (Fig-
ure 2G). Taken together, our data conclusively demonstrate
that CSCs bear reduced metabolic plasticity, mostly relying on
OXPHOS, and thus are not able to effectively induce glycolysis
to compensate for reduced ATP production upon mitochondrial
inhibition.
Mitochondrial Targeting Effectively Diminished CSCs
We have previously shown that metformin, which exerts consid-
erable inhibition of mitochondrial complex I, induced apoptosis
preferentially in CSC-enriched cultures while provoking cell-cy-
cle arrest in adherent cells (Lonardo et al., 2013). To demonstrate
a causal link to the reducedmetabolic plasticity of CSCs,metfor-
min was injected into the medium, resulting in a rapid and dose-
dependent drop in OCR, which became more apparent in low
Glc conditions (Figures 3A–3C). Indeed, metformin treatment
rendered spheres unable to respond to FCCP, which suggests
a disruption of the proton gradient consistent with complex I
inhibition, similar to the one provoked by rotenone (Figure 3D).
In addition, we found that long-term treatment with metformin
moderately inhibited mitochondrial oxygen consumption in
both CSC-enriched or -depleted conditions (Figure 3E), even
though the effect was more pronounced in spheres ranging
from 20%–60%. This was accompanied by an increment in
lactate production and NADPH accumulation (Figures 3F and
3G), most likely as a result of the relative enrichment of the
non-CSC fraction following preferential elimination of CSCs
as evidenced by a decline in the content of CD133+ cells
(Figure 3H).
The fact that a rather moderate inhibition of mitochondrial
oxygen consumption bymetformin induces such amarked reduc-
tion in CSCs indicates a particular vulnerability of CSCs to inhibi-
tion of mitochondrial function and renders this approach a poten-
tially attractive strategy to efficiently eliminate these highly
tumorigenic cells. To further validate this concept, we studied
other inhibitorsofmitochondrial function: the specificcomplex I in-
hibitor rotenone, the mitochondrial ROS inducer menadione, and
the ATP synthase inhibitor resveratrol (whichmay also affect other
cellular targets), which were all capable of dose-dependently in-
hibiting OCR (Figure 4A). When titrated to achieve an equivalent
level of OCR inhibition as induced by metformin, all compounds
decreased ATP content to a level similar to that of the ATP syn-
thase inhibitor oligomycin (Figure 4B) and subsequently induced
AMPKactivation in spheres (Figure 4C). Contrastingly, in adherent
cells these treatments rather enhanced lactate production (Fig-
ure 4D) and, as a result, these cells did not suffer from a pro-
nounced drop in ATP levels (data not shown), whereas the energy
crisis inCSC-enrichedcultures resulted inenhancedROSproduc-
tion and eventually apoptosis (Figures 4E, S4A, and S4B). This ef-
fect translated intosignificantlydecreasedCSCactivity invitro and
in vivo (Figures 4G–4I, S4C, and S4D).(C) ECAR simultaneously recorded to OCR as shown in (A).
(D) ECAR measurement in cells sorted for CD133 and subjected to sequential in
medium.
(E) Glycolytic capacity, measured as the percentage of ECAR increase after mito
(F) ATP kinetic following injection of oligomycin.
(G) ATP content after 6 hr of treatment with the indicated compounds.
Data are represented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. See al
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metformin transforming highly aggressive in vivo PDX models
into stable disease, tumors eventually progressed, irrespective
of concomitant treatment with gemcitabine (Lonardo et al.,
2013). As this represents a serious limitation for the proposed
treatment strategy, we aimed to reproduce such acquisition of
resistance in vitro for further mechanistic exploration. Indeed,
primary cultures derived from various PDX models became
resistant to metformin as well as resveratrol, although we did
not observe the outgrowth of resistant clones upon treatment
with menadione or rotenone over 60 days (Figure S4E). Consis-
tently, long-term treatment of spheres with menadione or rote-
none translated into a drastic decrease in CD133+ cells as well
as reduced sphere and colony formation, respectively (Figures
S4F and S4G). Together, these results corroborate our finding
that inhibition of mitochondrial activity induces energy crisis
and apoptosis in pancreatic CSCs. Importantly, however, resis-
tance seems to occur preferentially in metformin-treated cells
and was not apparent for menadione, which combines inhibition
of complex I and induction of ROS, rendering this approach a
promising strategy to more thoroughly eliminate CSCs.
Metformin-Resistant CSCs Display an Intermediate
Metabolic Phenotype
Next, we functionally compared untreated versus metformin-
treated tumors, both while still responsive as well as during
relapse (Figure 5A). First, we confirmed that tumors at different
stages expressed at least one of the transporters mandatory
for metformin uptake (OCT1-3) (Figure S5A). While metformin
treatment irreversibly depleted cancer-associated fibroblasts,
the cancer cell compartment, although greatly diminished during
the sensitive phase, eventually relapsed in resistant tumors (Fig-
ures 5B, S5B, and S5C). Importantly, the CSC content, defined
as EPCAM+ cells co-expressing either CD44, CD133, or
CXCR4, was reduced in sensitive tumors but had expanded
again in resistant tumors (Figures 5B andS5C). Consistently, plu-
ripotency-related genes were also decreased in sensitive tu-
mors, but expression levels had relapsed in resistant tumors
(Figure S5D). To elucidate whether resistance to metformin is
occurring in all contained CSC subclones or predominantly
occurring in certain subsets of CSCs, we tracked clonal distribu-
tion by implanting tumors stably expressing a barcode library.
Interestingly, relapsed tumors showed a reduced clonal hetero-
geneity as evidenced by enrichment for certain barcodes, indic-
ative of a positive selection and subsequent expansion of CSC
subclones during metformin treatment (Figure 5C). Interestingly,
however, CSCs contained in relapsing resistant tumors demon-
strated reduced stemness properties as demonstrated by dimin-
ished sphere formation capacity (Figure S5E) and content of
CSC marker positive cells (Figure S5F) as compared to sensitive
tumors.jections of glucose (Glc), oligomycin (O), and 2-deoxyglucose (2DG) into the
chondrial inhibition (left) or glucose and oligomycin injection (right).
so Figure S3.
c.
Figure 3. Metformin Inhibits Mitochondrial Respiration and Promotes Metabolic Reprogramming of CSCs
Adherent cultures or second-generation spheres were treated with 3 mM metformin (Met).
(A) OCR upon sequential metformin (M) injections. Rotenone (R) was used to completely block complex I activity.
(B) Percent OCR inhibition achieved by the indicated metformin doses or rotenone for decreasing glucose concentrations.
(C) Complex I activity inhibition by metformin, calculated as percentage of the inhibition obtained with rotenone, set as 100%.
(legend continued on next page)
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Subsequent analysis of the metabolic features of CSCs
(spheres or CD133+ cells) expanding under metformin treatment
indicated reduced basal andmitochondrial oxygen consumption
compared to treatment-naiveCSCs,while no significant changes
could be found in respective differentiated counterpart popula-
tions (Figures 5D and 5E). Consistently, resistant CSC-enriched
cultures showed increased glucose uptake (Figure S5G) and
13C-lactate release upon incubation with 13C-Glc (Figure S6A),
suggesting enhanced basal glycolytic activity. Indeed, resistant
CSCs displayed increased glycolytic capacity reaching levels
comparable to that of differentiated cells (Figure 5F). Interest-
ingly, further analysis by GC-MS indicated that resistant spheres
not only showed higher flux of 13C-Glc towards lactate as
compared to sensitive spheres, but also enhanced flux into the
PPP as evidenced by increased production of 13C-Ribose-5-P
(Figure S6B). However, no changes were found for 13C enrich-
ment in Krebs cycle intermediates (Figure S6C and data not
shown), suggesting that resistant spheres flux glucose into the
mitochondria as efficiently as sensitive ones. These data demon-
strate that a subset ofCSCs is equippedwith enhancedglycolytic
capacity, and therefore less susceptible to mitochondrial target-
ing, and eventually becomes the main driver of tumor propaga-
tion resulting in disease relapse. As such, while resistant cells
were still able to respond to mitochondrial targeting and showed
reduced complex I activity (Figure S5H), neither metformin nor
resveratrol were capable of inducing apoptosis in thesecells (Fig-
ure 5G), indicative of enhancedmetabolic plasticity. Interestingly,
as opposed to metformin, which bears long-term anti-oxidative
properties (Batandier et al., 2006), the ROS inducer menadione
still demonstrated significant toxicity, which may explain the
apparent lack of resistance to menadione (Figure S4).
MYC/PGC-1a Ratio Determines the Metabolic
Phenotype of CSCs
The outgrowth of CSC populations with an intermediate meta-
bolic phenotype following metformin treatment enabled us to
further elucidate the underlying molecular mechanism. First,
we compared the carbohydrate metabolism-related expression
profile of sensitive versus resistant CSC-enriched cultures
derived from three different PDX models. Sensitive spheres ex-
hibited increased expression of genes implicated in mitochon-
drial function and biogenesis (COQ10B, NDUFA5, PPARGC1A),
while MYC, capable of regulating both glycolysis and mito-
chondrial activity, was significantly suppressed compared to
adherent cells (Figures 6A and S6D). Expression levels in resis-
tant spheres reached intermediate levels positioned between
sensitive spheres and adherent cells, thus further corroborating
our finding that resistant CSCs bear an intermediate metabolic
phenotype. Moreover, withdrawal of metformin in resistant cells
reversed the metabolic phenotype toward that of sensitive ones,
with increased PGC1A levels and mitochondrial OCR (Figures
S6E and S6F). These data suggest that, indeed, the main feature(D) OCR upon sequential injection of metformin (M), FCCP (F), and antimycin + r
(E) Mitochondrial oxygen consumption at 96 hr.
(F) Lactate production in spheres on day 7.
(G) NADP+/NADPH ratio in spheres on day 7.
(H) CD133+ cell content as assessed by flow cytometry on day 7.
Data in (A)–(G) are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001
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is more receptive to changes in the environment.
To functionally validate the role of PGC-1a in determining
the metabolic features of CSCs, we knocked down PGC1A
in spheres using two different shRNA sequences cloned into an
inducible expression system. PGC1A expression levels were
reduced by at least 50% after 72 hr of doxycycline treatment,
which was accompanied by a consistent decrease in mitochon-
drial respiration (Figure 6B). In line with above studies, CSC
frequency as evidenced by sphere formation capacitywas signif-
icantly reduced (Figure 6C). As the outgrowth ofmetformin-resis-
tant CSCs suggested a certain degree of metabolic heterogene-
ity within the CSC compartment, we next isolated cells based on
CD133 expression and their mitochondrial mass as a surrogate
for PGC1A expression. As predicted, CD133+/Mitohigh cells
showed highest CSC activity, followed by CD133+/Mitolow cells,
as demonstrated by increased expression of pluripotency-asso-
ciated genes, in vitro self-renewal, and in vivo tumorigenicity
(Figures 6D–6F). Interestingly, CD133+/Mitohigh cells displayed
exclusive lethality in response to metformin treatment (Fig-
ure 6G), whereas CD133+/Mitolow cells were resistant to metfor-
min, although this came at the expense of reduced stemness.
MYC Inhibition Increases Mitochondrial Respiration,
Restoring Response to Metformin and Full Stemness in
Metformin-Resistant CSCs
Next, we investigated the role ofMYC for the metabolic features
of CSCs. Expression of MYC is tightly regulated by a complex
network of positive and negative regulators, in which miRNAs
play an important role (Jackstadt and Hermeking, 2015). Intrigu-
ingly, whileMYC expression did not correlate with miR-429 (data
not shown), MYC inversely correlated with the expression of
miR-34 (Figure S7A), amiRNA that demonstrably plays an impor-
tant role in pancreatic CSC self-renewal and cell-fate determina-
tion, respectively (Nalls et al., 2011). To further explore the contri-
bution ofMYC to the metabolic phenotype of pancreatic cancer
(stem) cells, we modulatedMYC expression by different means:
(1) pharmacological inhibition by JQ-1, which resulted in a dose-
dependent reduction of c-MYC expression (Figures 7A and 7B);
(2) MYC knockdown using two different inducible shRNAs (Fig-
ure 7B, lower left panel); and (3)MYC overexpression (Figure 7B,
lower right panel). Strikingly, PGC1A expression inversely
correlated with MYC expression, implying that MYC may act
as an upstream inhibitor of PGC-1a. As in silico prediction
also suggested that the PGC1A promoter bears three putative
MYC binding sites, we performed ChIP analysis, indicating that
MYC is indeed directly binding to the PGC1A promoter (Fig-
ure S7B), and luciferase reporter assays confirmed its inhibitory
activity on PGC1A expression (Figure S7C).
Consistently, MYC knockdown or pharmacological inhibition
of MYC resulted in enhanced PGC1A expression and sub-
sequently enhanced mitochondrial oxygen consumption, whileotenone (A+R) versus rotenone (R), FCCP (F), and antimycin (A).
.
c.
Figure 4. Diverse Panel of Mitochondrial Inhibitors Effectively Targets CSCs, Mimicking Metformin Effects
Except when indicated otherwise, adherent and second-generation sphere cultures were treated with 3 mM metformin (Met), 50 mM resveratrol (Resv), 10 mM
menadione (Mena), or 10 nM rotenone (Rot).
(A) OCR inhibition in spheres after 16 hr of treatment.
(B) ATP in spheres after 6 hr. Oligomycin (Oligo; 1 mM) was included as positive control.
(C) AMPK activation at 16 hr. Representative western blots for PDX-354.
(D) Lactate production in spheres at 72 hr.
(E) Percentage of apoptotic cells after 72 hr.
(F) Expression of pluripotency-related genes at 72 hr.
(legend continued on next page)
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the glycolytic capacity was inhibited. Moreover, when MYC inhi-
bition by JQ-1 was combined with knockdown of PGC1A, the in-
crease in mitochondrial OCR was no longer detectable (Figures
S7D and S7E), thus confirming that enhanced OXPHOS in
response to MYC suppression is indeed mediated by PGC1A.
On the other hand, MYC overexpression induced opposite
effects (Figure 7C). Strikingly, CD133+ CSCs overexpressing
MYC were no longer sensitive to mitochondrial targeting with
metformin (Figure 7D), thus mimicking the metabolic phenotype
of metformin-resistant CSCs, including their enhanced ability to
activate the glycolytic pathway upon mitochondrial inhibition
(Figure 7C). Importantly, as observed for resistant CSCs, MYC-
overexpressing cells also showed reduced stemness features
as compared to control cells (Figure 7E). These data suggest
that high mitochondrial activity represents an important deter-
minant of stemness. However, neither pluripotency genes nor
sphere formation was enhanced by MYC inhibition/knockdown
in differentiated cells (Figures 7E and S7F), demonstrating that
the distinct metabolic features of CSCs are a prerequisite for
stemness but are not sufficient to induce a CSC phenotype in
non-CSCs. Evenmore importantly,MYC inhibition or knockdown
was sufficient to prevent/reverse acquisition of resistance to
metformin (Figures 7F and 7G). These results confirmed that
increased MYC expression is indeed the mechanistic link for
the altered/distinct metabolic phenotype of resistant CSC with
enhanced glycolysis. Notably, MYC inhibition or knockdown
also enhanced stemness of resistant CSCs, as evidenced by
increased pluripotency gene expression, self-renewal capacity,
and CD133+ cell content (Figures 7H and 7I). These data confirm
that highOXPHOSactivity ismandatory for full CSC functionality.
DISCUSSION
To cope with the metabolic needs of high proliferation, cancer
cells preferentially generate ATP via glycolysis, even under nor-
moxic concentrations (Warburg effect). Similarly, highly prolifera-
tive iPS cells and somatic stem cells (e.g., hematopoietic stem
cells), but interestingly also more quiescent long-term hemato-
poietic and neural stem cells, are also mainly glycolytic, while
their respective progenies switch to OXPHOS (Shyh-Chang
et al., 2013; Varum et al., 2011). The metabolic phenotype of
CSCs appears to vary across tumor types.While in breast cancer
and nasopharyngeal carcinomaCSCswere found to be predom-
inantly glycolytic (Dong et al., 2013; Lin et al., 2013; Schieber and
Chandel, 2013), CSCs in glioma and glioblastoma (Janiszewska
et al., 2012; Vlashi et al., 2011), lung cancer (Ye et al., 2011),
and leukemia (Gurumurthy et al., 2010; Lagadinou et al., 2013;
Nakada et al., 2010) appear to rely on mitochondrial OXPHOS.
Here,wenowshow that humanpancreaticCSCs,whosemeta-
bolic phenotype had not been defined to date, obtain their energy
mainly through mitochondrial OXPHOS, whereas non-CSCs
show the expected Warburg phenotype. Interestingly, it was(G) Sphere formation after 7 days. Cells/tumors were pretreated for 5 days in vitr
(H) Respective data for surface expression of CD133.
(I) In vivo tumorigenicity assay. 103 or 104 cells from PDX-215 and 354 were pretrea
table summarizing the number of tumors obtained after 15 weeks. Bottom: repr
tumor take upon injection of 103 PDX-215 cells.
Data are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. See also
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cer cells, which had survived Kras ablation, were also mainly de-
pending on OXPHOS (Viale et al., 2014). Similar to human CSCs
described here, the authors demonstrate in Kras-expressing tu-
mors the existence of a CD133+ subpopulation with high mito-
chondrial mass and hyperpolarized mitochondria, suggesting
that CD133+/Mitohigh cells can be found in pancreatic tumors of
murine and human origin. After Kras ablation, surviving cells
were characterized by strong dependency on mitochondrial
metabolism and limited metabolic plasticity, which could be
attributed to the shutdown of the metabolic program driven by
Kras. In contrast, however, we find that human CSCs derived
from a large panel of PDX models, all carrying activating KRAS
mutations identical to those found in their epigenetically defined
progenies (non-CSCs), bear a distinct metabolic phenotype
with limited plasticity that is controlled by MYC. Strikingly,
CSCs from another PDX model carrying wild-type KRAS (PDX-
354) showeda similarmetabolic phenotype, further corroborating
that the lack of plasticity is independent of the Kras mutational
status. Moreover,Kras-ablatedmurine cells required reactivation
ofmutantKras for proliferationand tumor relapse, suggesting that
the observed OXPHOS phenotype is restricted to oncogene-ab-
lated dormant cells, as opposed to the highly tumorigenic CSCs
studied here.
Mechanistically, we found that lowMYC expression in human
CSCs allowed high PGC1A expression levels, which resulted in
enhanced mitochondrial biogenesis, strong mitochondrial activ-
ity and antioxidant properties, and subsequently low mitochon-
drial ROS levels, as a prerequisite for their stemness functions.
Intriguingly, sustained suppression of MYC was required for
maintaining stemness but renderedCSCs unable to substantially
activate glycolysis and thus highly susceptible to mitochondrial
targeting, e.g., by metformin or menadione. MYC promotes a
Warburg-like glycolytic phenotype, probably via dual mecha-
nism: (1) upregulation of key glycolytic enzymes and (2) suppres-
sion of PGC1A. The latter is a transcriptional co-activator
for nuclear receptor PPARs, which allows the protein to inter-
act with multiple transcription factors, e.g., cAMP response
element-binding protein (CREB) and nuclear respiratory factors
(NRFs) (Fernandez-Marcos and Auwerx, 2011). While it is known
that proteasomal degradation inhibits PGC-1a (Ahuja et al.,
2010), we here show for the first time a direct inhibitory effect
of MYC on PGC-1a at the transcriptional level, upon MYC bind-
ing to the PGC1A promoter.
Interestingly, whileMYC has been linked to stemness proper-
ties in other tumors, e.g., hepatocellular carcinoma, breast, and
lung cancer (Akita et al., 2014; Zhao et al., 2015), we found in
PDAC that MYC was associated with a more differentiated
phenotype andMYC overexpression actually reduced stemness
in CSCs (Figure 7). Notably, while suppression of MYC was
essential for maintaining CSC phenotypes, the mere inhibition
ofMYC in non-CSCs did not equip themwith stemness features.o or treated for 15 days in vivo.
ted for 7 days with the indicated inhibitors and then injected intomice. Top left:
esentative images of tumors obtained for PDX-215cells. Top right: kinetics of
Figure S4.
c.
Figure 5. Metformin-Resistant CSCs Display an Intermediate Metabolic Phenotype
PDX-A6L, 185, and 286 tissue was implanted, and once tumors had reached an average volume of 100 mm3, mice were randomized for 150 mg/Kg/day
metformin or vehicle.
(A) Tumor growth curves. Squares indicate when sensitive and resistant tumors, respectively, were harvested.
(B) EPCAM (top panel) and CD44/CD133 (bottom panel) staining was assessed by flow cytometry. Size-matched tumors were treated with vehicle or metformin.
(C) Percentage of tumor composed by the most abundant individual barcodes, following 6 weeks of treatment.
(D) OCR measurements. O, oligomycin; F, FCCP; A+R, antimycin + rotenone.
(E) Mitochondrial OCR.
(F) Glycolytic capacity after Glc+oligomycin injection, comparing CD133– and CD133+ cells obtained from either sensitive or resistant cultures.
(G) Apoptosis induction in CD133+ cells derived from sensitive and resistant cultures upon 72 hr of treatment.
Data in (A) and (C)–(G) are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S5.
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Figure 6. MYC/PGC-1a Ratio Determines the Metabolic Phenotype of CSC
(A) PGC1A and MYC expression as determined by real-time PCR in treatment-naive CD133+ versus CD133– cells derived from either sensitive or resistant
cultures. Data are represented at logarithmic scale, relative to CD133– cells. Pooled data from PDX-215, 253, and 354.
(B) PDX-215 cells were transduced with two different inducible shRNA lentiviral constructs against PGC-1a and then cultured in the presence or absence of
2 ng/ml doxycycline. PGC-1a levels as assessed by western blot (top panel) and mitochondrial OCR (bottom panel).
(C) Sphere formation upon knockdown of PGC-1a.
(D) Left, representative CD133/mitochondrial mass staining. Right, expression of pluripotency-related genes and PGC1A in the sorted populations.
(E) Mitochondrial OCR (black bars) and sphere formation capacity (gray bars).
(legend continued on next page)
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In addition, building on prior evidence that PGC-1a is crucial for
the anti-oxidative capacity and mitochondrial metabolism in
cancer (Haq et al., 2013; LeBleu et al., 2014; Vazquez et al.,
2013), we now demonstrate that PGC-1a also maintains
CSC self-renewal capacity, probably by controlling intracellular
ROS levels. Importantly, metformin-resistant CSCs display
decreased PGC-1a levels and thus enhanced intracellular ROS
levels, which negatively impacted their self-renewal capacity
but still allowed them to promote disease relapse in the presence
of metformin. Together, these data indicate that the distinct
metabolic features of CSCs are a prerequisite for CSC functions
in PDAC, but other cell-specific signals, e.g., Nodal/Activin, are
required for the CSC phenotype (Lonardo et al., 2011).
Our data also suggest that the metabolic phenotype of CSCs
is heterogeneous. While the majority of CSCs was depending on
OXPHOSwith very limitedmetabolic plasticity, a subset of CSCs
that was small in treatment naive tumors but strongly expanded
in metformin-resistant tumors, was characterized by an interme-
diate and more adaptable metabolic phenotype. These cells
were identified as CD133+/Mitolow cells and showed reduced
mitochondrial mass and stemness but also enhanced metabolic
plasticity and inherent resistance to metformin (Figures 6D–6G).
The diminished clonal heterogeneity found in metformin-resis-
tant tumors and their global intermediate phenotype, reminis-
cent of above CD133+/Mitolow cells (Figure 5C), strongly sug-
gests that pre-existing metabolic heterogeneity in pancreatic
CSCs is the main driver of relapse under metformin treatment.
Indeed, while epidemiological and preclinical evidence was
strongly supporting the use of metformin as a new treatment op-
tion for pancreatic cancer, first clinical trials have been disap-
pointing (Carvalho et al., 2014; Kordes et al., 2015; Wilmink
et al., 2014). Dosage has been a main concern for this apparent
lack of translatability. In the clinic, metformin is administered at
anti-diabetic doses (500–1,000 mg/day), which corresponds to
the 250 mg/kg/day in mice, and regularly results in plasma con-
centrations in the micromolar range. In vitro inhibition of cancer
cell proliferation, however, has been reported for millimolar
concentrations (Lonardo et al., 2013; Rizos and Elisaf, 2013).
Notably, glucose levels are an important determinant of met-
formin response. As opposed to the usual hyperglycemic cell
culture conditions (e.g., 17.5 mM in DMEM/F-12), the required
metformin dose for targeting CSCs in normal or low Glc condi-
tions (5 mM and 1 mM, respectively) is substantially lower
(100 mM, Figure 3B) and in fact does correspond to achievable
plasma concentrations in vivo. Moreover, at least in mice using
the above dosing scheme, substantial tumor inhibition including
a significant depletion of the CSC content has been achieved,
even though these effects were not lasting (Lonardo et al.,
2013; Oliveras-Ferraros et al., 2014). Thus, the outgrowth of
drug-resistant CSC clones during metformin treatment could at
least in part explain the limited response in patients.
Intriguingly, in the present study, no resistance was observed
for another mitochondria-targeting agent, i.e., menadione. As
opposed to metformin, the compound is undergoing futile redox(F) Left, percentage of tumors obtained after injection of indicated numbers of
software.
(G) Apoptosis upon 72 hr treatment with metformin.
Data are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
Cellcycles on the respiratory chain subsequently inducing ROS (Pet-
ronilli et al., 1994). Therefore, menadione is likely to affect CSC
functionality by dual mechanism, oxidizing several mitochondrial
proteins as well as inducing mitochondrial ROS that alter the
intricate redox equilibrium critical for maintaining both survival
and self-renewal of CSCs (Diehn et al., 2009). This may explain
the lack of resistance to menadione and thus may represent an
interesting new opportunity for mitochondrial targeting in
PDAC. Alternatively, combining metformin with MYC inhibition,
e.g., using the BRD4 inhibitor JQ-1, prevented or reversed,
respectively, resistance to metformin by enforcing their depen-
dence on OXPHOS, suggesting a new multimodal approach
for targeting the distinct metabolic features of pancreatic CSCs.
EXPERIMENTAL PROCEDURES
Primary Human PDAC Cells
For primary cultures, PDX-derived tumor tissue fragments were minced, enzy-
matically digested with collagenase (Stem Cell Technologies) for 90 min at
37C (Mueller et al., 2009), and after centrifugation for 5 min at 1,200 rpm
the pellets were resuspended and cultured in RPMI, 10% FBS, and 50 units/
ml penicillin/streptomycin.
Cancer Stem Cell-Enriching Culture
PDAC spheres were generated and expanded in DMEM-F12 (Invitrogen) sup-
plemented with B-27 (GIBCO) and bFGF (PeproTech EC). 103 cells/ml were
seeded in ultra-low attachment plates (Corning) as described previously (Gall-
meier et al., 2011). For serial passaging, spheres were harvested at day 7 using
a 40 mmcell strainer, dissociated to single cells with trypsin, and then re-grown
in the same conditions for 7 days. Number of spheres >40 mmwere determined
using a CASY Cell Counter (Roche).
Flow Cytometry and Cell Sorting
Primary pancreatic cells (adherent monolayers or dissociated cells from
sphere cultures) were resuspended in Sorting buffer (13 PBS; 3% FBS [v/v];
3 mMEDTA [v/v]) before analysis or sorting with a FACS Canto II or FACS Influx
instrument, respectively (BD). To identify pancreatic CSCs, the following anti-
bodies were used: anti-CD133/1-APC or PE; (Miltenyi), anti-CXCR4-APC,
SSEA-1-APC, EPCAM-FITC, CD44-PE (all from eBiosciences), or appropriate
isotype-matched control antibodies. DAPI was used for exclusion of dead cells
(eBiosciences). All samples were analyzed by flow cytometry using a FACS
Canto II (BD), and data were analyzed with FlowJo 9.2 software (Tree Star).
XF Extracellular Flux Analyzer Experiments
Single-cell suspensions from trypsinized secondary spheres/adherent cul-
tures or cells sorted for CD133 were plated in XF96 Cell Culture Microplates
(Seahorse Bioscience) previously coated with Cell-Tak (BD Biosciences) at a
cellular density of 30,000 cells/well. For OCR determination, cells were incu-
bated in base assay medium (D5030, Sigma) supplemented with 2 mM gluta-
mine, 10 mM glucose, and 1 mM pyruvate for 1 hr, prior to the measurements
using the XF Cell Mito Stress Kit (Seahorse Bioscience). Concentrations of
oligomycin and FCCP were adjusted for each primary cell type. For glycolytic
metabolism measurements, cells were incubated in basal media prior to injec-
tions using the Glycolytic Test kit (Seahorse Bioscience). For evaluation of
the response to metformin, 3 mM metformin was injected in ports A–C, and
percentage of complex I inhibition was calculated as the percentage of OCR
inhibited upon metformin injection with respect to the inhibition obtained
with rotenone, used as 100%. Alternatively, sequential injection of metformin,
FCCP, and antimycin + rotenone versus rotenone, FCCP, and antimycin werecells. Right, CSC frequency, calculated from tumorigenicity data using ELDA
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Figure 7. MYC Inhibition Increases Mitochondrial Respiration, Restoring Response to Metformin and Full Stemness in Metformin-Resistant
Cells
(A–E) Parental PDX-215 cells or 215 expressing either two different inducible lentiviral MYC shRNA constructs (sh1, sh2) or a MYC overexpression construct (OE)
were used.
(A) PGC1A and MYC mRNA expression levels in cells treated for 72 hr with increasing concentrations of the MYC inhibitor JQ-1.
(B) PGC-1a and MYC protein expression levels. Tubulin was used as loading control.
(C) Mitochondrial OCR and glycolytic capacity.
(D) Apoptosis as assessed by Annexin/DAPI staining, upon 72 hr of metformin treatment.
(legend continued on next page)
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carried out. Experiments were run in a XF96 analyzer (Seahorse Bioscience),
and raw data were normalized to protein content.
In Vivo Tumorigenicity Assay
Pretreated/sorted cells were trypsinized, resuspended in 50 ml of Matrigel, and
then subcutaneously injected into female 6- to 8-week-old NU-Foxn1nu nude
mice (Harlan Laboratories). Tumor growth was monitored weekly for up to
4 months. Procedures were conducted in accordance with the institutional
and national regulations (Ethics Committee of the Instituto de Salud Carlos
III, Madrid, Spain; Protocol PA 34_2012 and Animals in Science Regulation
Unit, Home Office Science, London, UK; Project License PPL70/8129).
In Vivo Treatments
NU-Foxn1nu nude mice (6–8 weeks of age) were purchased from Charles
Rivers or Harlan Laboratories. Tumor pieces were subcutaneously implanted,
and when tumors reached a volume of 100 mm3, mice were randomized into
treatment groups: metformin (drinking water, 150 mg/kg), resveratrol (subcu-
taneous, 25 mg/kg), menadione (i.p., 20 mg/kg), and rotenone (subcutaneous,
0.5 mg/kg). For CSC evaluation, mice were sacrificed after 15 days of treat-
ment, tumors digested, and assessed for CD44+CD133+ CSC content and
sphere formation capacity. Mice were housed according to institutional guide-
lines, and procedures were conducted in accordance with the institutional and
national regulations (Ethics Committee of the Instituto de Salud Carlos III,
Madrid, Spain; Protocol PA 34_2012 and Animals in Science Regulation
Unit, Home Office Science, London, UK; Project License PPL70/8129).
RNA-Seq Library Construction and Analysis Method
Total RNA was isolated by the guanidine thiocyanate method using standard
protocols. PolyA+ RNA fraction was processed as in Illumina’s ‘‘TruSeq
RNA Sample Preparation v2 Protocol’’ (Part # 15026494 Rev. C). The resulting
purified cDNA library was applied to an Illumina flow cell for cluster generation
(TruSeq cluster generation kit v5) and sequenced on the Genome Analyzer IIx
with SBS TruSeq v5 reagents by following manufacturer’s protocols. Tran-
script assembly and estimation of their abundances were calculated with Cuf-
flinks 1.3.0 (Trapnell et al., 2012), using the human genome annotation dataset
Homo_sapiens.GRCh37.65 from Ensembl (Flicek et al., 2014). Differential
expression for genes across the different conditions was calculated with Cuff-
diff (Trapnell et al., 2012). Principal component analysis (PCA) figures showing
how samples clustered was obtained with R (http://www.r-project.org/).
Heatmaps showing gene expression levels (in FPKM, fragments per kilobase
of transcript per million mapped fragments) through the different samples
were drawn with GENE-E (http://www.broadinstitute.org/cancer/software/
GENE-E/) for a subset of selected genes. Data deposited in ArrayExpress:
E-MTAB-3808. More details are available in the Supplemental Information.
Statistical Analyses
Results for continuous variables are presented as means ± SEM unless stated
otherwise. Treatment groups were compared with the independent samples
t test. Pair-wise multiple comparisons were performed with the one-way
ANOVA (two-sided)withBonferroni adjustment.pvalues<0.05wereconsidered
statistically significant. All analyses were performed using SPSS 22.0 (SPSS).
Full description of Experimental Procedures is available in the Supplemental
Information.
ACCESSION NUMBERS
The Array Express accession number for the RNA-seq experiment reported in
this paper is E-MTAB-3808.(E) Sphere formation assay.
(F) PDX-185 and 215 cells were treated for 21 days with metformin alone or in com
of treatment to evaluate the emergence of resistant clones.
(G–J) Parental metformin-resistant cells or cells expressing different inducible le
(G) Apoptosis induction in metformin-resistant cells upon 72 hr treatment with me
(H) Expression of mRNA for pluripotency genes.
(I) Sphere formation assay.
(J) Content of CD133+ cells. Data are presented as mean ± SEM. *p < 0.05, **p <
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